Juan L Coelho-Silva

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1621510/publications.pdf

Version: 2024-02-01

46 papers	351 citations	840776 11 h-index	888059 17 g-index
49 all docs	49 docs citations	49 times ranked	575 citing authors

#	Article	IF	Citations
1	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood, 2020, 135, 870-875.	1.4	48
2	Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, 2018, 73, e566s.	1.5	35
3	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Letters, 2019, 456, 59-68.	7.2	31
4	High Î”Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood, 2015, 126, 2302-2306.	1.4	28
5	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, 2020, 5, 5.	17.1	26
6	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. Blood, 2019, 134, 951-959.	1.4	21
7	PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. Cancer Genetics, 2019, 233-234, 56-66.	0.4	21
8	Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. Cellular Oncology (Dordrecht), 2021, 44, 1105-1117.	4.4	16
9	Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death and Disease, 2018, 9, 311.	6.3	14
10	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, 2020, 38, 733-745.	2.6	13
11	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Advances, 2020, 4, 2339-2350.	5.2	11
12	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells. Heliyon, 2017, 3, e00405.	3.2	9
13	Prognostic importance of <scp>CD</scp>56 expression in intermediate risk acute myeloid leukaemia. British Journal of Haematology, 2017, 176, 498-501.	2.5	8
14	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. Blood Advances, 2017, 1, 1807-1814.	5.2	8
15	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 2021, 39, 736-746.	2.6	7
16	Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. Cellular Oncology (Dordrecht), 2020, 43, 1191-1201.	4.4	6
17	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. Leukemia and Lymphoma, 2021, 62, 147-157.	1.3	6
18	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 2022, 40, 438-452.	2.6	6

#	Article	IF	Citations
19	Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia. Haematologica, 2017, 102, e43-e46.	3.5	5
20	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Scientific Reports, 2020, 10, 10315.	3.3	5
21	MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. Cell Death and Disease, 2021, 12, 371.	6.3	5
22	Alpha thalassemia, but not Î²S-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort. Annals of Hematology, 2021, 100, 921-931.	1.8	3
23	Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET). Blood, 2019, 134, 554-554.	1.4	3
24	Î”Np73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget, 2017, 8, 8475-8483.	1.8	3
25	Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival. Applied Cancer Research, 2018, 38, .	1.0	2
26	Association between ANXA2*5681 polymorphism (rs7170178) and osteonecrosis in haemoglobin SSâ€genotyped patients. British Journal of Haematology, 2020, 188, e8-e11.	2.5	2
27	Association of HMIP1 C-893A polymorphism and disease severity in patients with sickle cell anemia. Hematology, Transfusion and Cell Therapy, 2020, 43, 243-248.	0.2	2
28	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, 2021, 11, 1675.	3.3	2
29	Interleukinâ€6 Gâ€174C polymorphism predicts higher risk of stroke in sickle cell anaemia. British Journal of Haematology, 2018, 182, 294-297.	2.5	1
30	The ratio of ATP11C/PLSCR1 mRNA transcripts has clinical significance in sickle cell anemia. Annals of Hematology, 2021, , 1.	1.8	1
31	Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell. Blood, 2019, 134, 1682-1682.	1.4	1
32	Suppression of multiple antiâ€apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science, 2021, , .	3.9	1
33	Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, 2022, 83, 105384.	2.4	1
34	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. Blood Advances, 2017, 1, 86-89.	5.2	0
35	Autophagy Inhibition Potentiates Ruxolitinib-Induced Apoptosis in JAK2V617F Cells. Blood, 2018, 132, 1788-1788.	1.4	0
36	Clinical Impact and Therapeutic Opportunity of Insulin Receptor Substrates 1/2 in Acute Myeloid Leukemia. Blood, 2018, 132, 1512-1512.	1.4	0

#	Article	IF	Citations
37	IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia. Blood, 2019, 134, 2689-2689.	1.4	0
38	MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors. Blood, 2019, 134, 1403-1403.	1.4	0
39	Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model. Blood, 2019, 134, 2977-2977.	1.4	0
40	Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts. Blood, 2019, 134, 2602-2602.	1.4	0
41	Molecular-Based Score Inspired on Metabolic Signature Improves Prognostic Stratification for Myelodysplastic Syndrome. Blood, 2019, 134, 4257-4257.	1.4	0
42	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 5166-5166.	1.4	0
43	Clinical Significance of Mitochondrial DNA Content in Acute Promyelocytic Leukemia. Blood, 2021, 138, 3474-3474.	1.4	0
44	IGF1R-IRS1/2 Pharmacological Inhibitors Act By Distinct Cellular and Molecular Mechanisms and Reveals Vulnerabilities for Treatment of Acute Myeloid Leukemia. Blood, 2021, 138, 1869-1869.	1.4	0
45	Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, 2022, , 1.	2.6	0
46	Irs1S57X Heterozygous Mutant Mice Display Normal Hematopoiesis and Phenotypic Features, While Homozygous Knockout Exhibit High Fetal or Postnatal Lethality. Blood, 2020, 136, 33-34.	1.4	0